# Continuous secretory production in E. coli enables scalable, high-titer manufacturing of active recombinant endonucleases

**Authors:** Sudarsana Reddy Lokireddy, Chennakesavulu Thummadhi, Pratyusha Godavarty, Venkateswarlu Petla, Akhila Munimanda, Sridhar Rao Kunchala, Ramakrishna Vadde

PMC · DOI: 10.1186/s13036-025-00590-0 · Journal of Biological Engineering · 2025-12-15

## TL;DR

A new method in E. coli enables high-yield production of active endonucleases without harming the host cells, supporting various biopharmaceutical applications.

## Contribution

The study introduces a scalable and cost-effective system for producing active endonucleases using secretion in E. coli.

## Key findings

- Secreted DRNase® achieved 1 g/L in fermentation and showed higher activity than commercial products.
- Bovine DNase I secreted via the system retained strong activity and is suitable for mRNA vaccine production.
- The BacSec® platform enables tag-free, high-titer endonuclease production with long-term stability.

## Abstract

Recombinant endonucleases are essential for biopharmaceutical manufacturing and molecular biology workflows, yet their intracellular expression in Escherichia coli often leads to host cell toxicity due to non-specific DNA and RNA degradation. To address this, we employed the BacSec® system to secrete Serratia marcescens non-specific endonuclease, nucA (DRNase®) and bovine DNase I in E. coli, aiming to mitigate cytotoxicity and streamlined downstream processing. DRNase® was efficiently secreted, enabling simplified purification at the shake flask level and achieving 1 g/L in high-density fermentation, with over 2 g/L in perfusion-based fermentation. The secreted DRNase® was predominantly monomeric, demonstrated higher specific activity than commercial counterparts, and remained stable at room temperature for over a year. Likewise, secreted bovine DNase I retained strong enzymatic activity without degrading mRNA, making it particularly suitable for mRNA vaccine production. These secreted endonucleases support a wide range of industrial applications, including biologics production, gene therapy, mRNA and viral vector-based vaccines, and therapeutic use. Overall, the BacSec® platform, integrated with perfusion fermentation, provides a scalable, tag-free, and cost-effective solution for high-titer production of active endonucleases.

The online version contains supplementary material available at 10.1186/s13036-025-00590-0.

## Linked entities

- **Proteins:** Nuca (dominant nuclear cataract)
- **Species:** Escherichia coli (taxon 562), Serratia marcescens (taxon 615)

## Full-text entities

- **Genes:** HlyA [NCBI Gene 7701379], hemolysin A [NCBI Gene 3654480]
- **Diseases:** cytotoxicity (MESH:D064420), respiratory diseases (MESH:D012140), inflammatory (MESH:D007249)
- **Chemicals:** TFA (MESH:D014269), thiamine (MESH:D013831), amino acid (MESH:D000596), glycerol (MESH:D005990), BCA (-), sodium bicarbonate (MESH:D017693), H2SO4 (MESH:C033158), Glucose (MESH:D005947), PBS (MESH:D007854), Tween-20 (MESH:D011136), Agarose (MESH:D012685), IPTG (MESH:D007544), Q (MESH:D005973), ATP (MESH:D000255), carbon (MESH:D002244), acetonitrile (MESH:C032159), Oxygen (MESH:D010100), ammonia (MESH:D000641), formic acid (MESH:C030544), NaCl (MESH:D012965), MgCl2 (MESH:D015636), blood glucose (MESH:D001786), NaOH (MESH:D012972), Kanamycin (MESH:D007612), SDS (MESH:D012967), DTT (MESH:D004229), oligonucleotides (MESH:D009841), CaCl2 (MESH:D002122), Flux (MESH:C040639), peptide (MESH:D010455), nucleotide (MESH:D009711), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606], Serratia marcescens (species) [taxon 615], Escherichia coli (E. coli, species) [taxon 562]
- **Mutations:** S090744490000322X, H184N, I in 10, H184A, H184R, H184T
- **Cell lines:** BOP2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628), BL21 (DE3) — Mus musculus (Mouse), Hybridoma (CVCL_B7HM)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12822159/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12822159/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12822159/full.md

---
Source: https://tomesphere.com/paper/PMC12822159